To address this, stromal-targeting agents such as calcipotriol and losartan are being investigated to enhance drug delivery, while immunotherapies, such as anti-PD-L1 (anti-Programmed Cell Death Ligand 1), are being tested to activate the immune system against the tumor [5, 13, 14, 15]. This evidence concerns the gene CD274 and neoplasm.